Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-10376568-B2
Application number	US-201816210330-A
Country	US
Kind code	B2
Filing date	Dec 5, 2018
Priority date	Aug 5, 2015
Publication date	Aug 13, 2019
Grant date	Aug 13, 2019

Abstract

A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.

First claim

The invention claimed is:

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that aberrantly present a peptide consisting of the amino acid sequence of LYFEKGEYF (SEQ ID NO: 55),
wherein said cancer is selected from the group consisting of lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, and prostate cancer.

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , wherein the activated T cells are expanded in vitro.

6. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

7. The method of claim 6 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL- 21, and IL-23.

9. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that presents the peptide in a complex with an MEW class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

10. The method of claim 9 , wherein the contacting is in vitro.

11. The method of claim 1 , wherein the cancer is lung cancer.

12. The method of claim 1 , wherein the cancer is gastric cancer.

13. The method of claim 1 , wherein the cancer is esophageal cancer.

14. The method of claim 1 , wherein the cancer is brain cancer.

15. The method of claim 1 , wherein the activated T cells release a cytokine.

16. The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of LYFEKGEYF (SEQ ID NO: 55).

17. A method of eliciting an immune response in a patient who has lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, or prostate cancer, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt and an adjuvant, wherein said peptide consisting of the amino acid sequence of LYFEKGEYF (SEQ ID NO: 55), thereby inducing a T-cell response to the lung cancer, melanoma, liver cancer, breast cancer, uterine cancer, Merkel cell carcinoma, pancreatic cancer, gallbladder cancer, bile duct cancer, colon or rectum cancer, urinary bladder cancer, kidney cancer, leukemia, ovarian cancer, esophageal cancer, brain cancer, gastric cancer, or prostate cancer.

18. The method of claim 17 , wherein the T cell response is a cytotoxic T cell response.

19. The method of claim 17 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

20. The method of claim 17 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of LYFEKGEYF (SEQ ID NO: 55).

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• G01N33/6848

  Methods of protein analysis involving mass spectrometry · CPC title